Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Melt Pharmaceuticals, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Provides Corporate Update
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
From Melt Pharmaceuticals, Inc.
Via Business Wire
Tickers HROW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.